Literature DB >> 30524906

miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.

Ailiang Zeng1,2, Jianxin Yin3, Zheng Wang2, Chuanbao Zhang3, Rui Li1, Zhuoran Zhang1, Wei Yan1, Yongping You1.   

Abstract

GBM tissues are comprised of not only tumor cells but also tumor-associated nontumor cells, such as stromal cells and immune cells, which dilute the purity of glioma cells and function in glioma biology. However, the roles of miRNAs in modulating glioma purity are not clarified. In total, 838 glioma samples with transcriptome data, including 537 RNAseq data from TCGA project and 301 microarray data from Chinese Glioma Genome Atlas (CGGA project), were recruited into our investigation. Tumor purity, molecular subtypes and IDH status were also available. R language was employed as the main tool for statistical analysis and graphical work. Screening miRNA profiling and paired TCGA samples' transcriptome data demonstrates that miR-17-5p expression harbors the most significant positive correlation with glioma purity among all miRNAs. CXCL14 shows robust negative correlation with miR-17-5p expression in TCGA and CGGA dataset. miR-17-5p directly targets CXCL14 and functions as a tumor-suppressor of GBM. CXCL14 showed lower expression in proneural subtype and may contribute as a potential marker for proneural subtype in glioma. Genes markedly correlated with CXCL14 are involved in essential functions associated with anti-tumor immune process. CXCL14 has a strong correlation with immune(T cells, Monocytic lineage and Neutrophils) and Fibroblasts within glioma environment. miR-17-5p and CXCL14 exhibited predictive values for high-grade glioma(HGG) patients: Higher miR-17-5p indicated significantly longer survival while lower CXCL14 indicated longer survival. Our results highlight the importance of the miR-17-5p-CXCL14 axis in regulating key steps of anti-tumor immune process and may serve as potential targets of immune treatments for gliomas.

Entities:  

Keywords:  CXCL14; Glioma; immune response; miR-17-5p

Year:  2018        PMID: 30524906      PMCID: PMC6279316          DOI: 10.1080/2162402X.2018.1510277

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  42 in total

1.  Tumor Purity as an Underlying Key Factor in Glioma.

Authors:  Chuanbao Zhang; Wen Cheng; Xiufang Ren; Zheng Wang; Xing Liu; Guanzhang Li; Sheng Han; Tao Jiang; Anhua Wu
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

2.  MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.

Authors:  Xie-Feng Wang; Zhu-Mei Shi; Xi-Rui Wang; Lei Cao; Ying-Yi Wang; Jun-Xia Zhang; Yu Yin; Hui Luo; Chun-Sheng Kang; Ning Liu; Tao Jiang; Yong-Ping You
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-30       Impact factor: 4.553

Review 3.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

4.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

5.  CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.

Authors:  Martin Augsten; Christina Hägglöf; Eleonor Olsson; Claudia Stolz; Panagiotis Tsagozis; Tetyana Levchenko; Mitchell J Frederick; Ake Borg; Patrick Micke; Lars Egevad; Arne Ostman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

6.  c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.

Authors:  Hui Luo; Zhengxin Chen; Shuai Wang; Rui Zhang; Wenjin Qiu; Lin Zhao; Chenghao Peng; Ran Xu; Wanghao Chen; Hong-Wei Wang; Yuanyuan Chen; Jingmin Yang; Xiaotian Zhang; Shuyu Zhang; Dan Chen; Wenting Wu; Chunsheng Zhao; Gang Cheng; Tao Jiang; Daru Lu; Yongping You; Ning Liu; Huibo Wang
Journal:  Brain       Date:  2015-10-08       Impact factor: 13.501

7.  A Crucial Role of CXCL14 for Promoting Regulatory T Cells Activation in Stroke.

Authors:  Hsu-Tung Lee; Shih-Ping Liu; Chen-Huan Lin; Sophie Wei Lee; Chung Y Hsu; Huey-Kang Sytwu; Chia-Hung Hsieh; Woei-Cherng Shyu
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

Review 8.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

9.  CXCL14: the Swiss army knife chemokine.

Authors:  Charaf Benarafa; Marlene Wolf
Journal:  Oncotarget       Date:  2015-10-27

Review 10.  MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Authors:  Amanda Shea; Varsha Harish; Zainab Afzal; Juliet Chijioke; Habib Kedir; Shahnoza Dusmatova; Arpita Roy; Malathi Ramalinga; Brent Harris; Jan Blancato; Mukesh Verma; Deepak Kumar
Journal:  Cancer Med       Date:  2016-06-10       Impact factor: 4.452

View more
  6 in total

1.  Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.

Authors:  Menha Swellam; Noha M Bakr; Hekmat M El Magdoub; Marwa S Hamza; Lobna R Ezz El Arab
Journal:  J Mol Neurosci       Date:  2020-09-28       Impact factor: 3.444

2.  miR-720 is a key regulator of glioma migration and invasion by controlling TARSL2 expression.

Authors:  Yinlong Liu; Kuan Jiang; Tongle Zhi; Xiupeng Xu
Journal:  Hum Cell       Date:  2021-05-23       Impact factor: 4.174

3.  Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis.

Authors:  Ali Mohamed Alshabi; Basavaraj Vastrad; Ibrahim Ahmed Shaikh; Chanabasayya Vastrad
Journal:  Biomolecules       Date:  2019-05-24

4.  Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer.

Authors:  Zhe Gong; Jieyun Zhang; Weijian Guo
Journal:  Cancer Med       Date:  2020-10-08       Impact factor: 4.452

5.  The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.

Authors:  Xinke Xu; Hongyao Yuan; Junping Pan; Wei Chen; Cheng Chen; Yang Li; Fangcheng Li
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

6.  miR-637 Prevents Glioblastoma Progression by Interrupting ZEB2/WNT/β-catenin Cascades.

Authors:  Wei Wang; Zilong Zhao; Shuai Han; Di Wu
Journal:  Cell Mol Neurobiol       Date:  2021-05-28       Impact factor: 4.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.